diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md
index e48c6de3d..7a7616275 100644
--- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md	
+++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md	
@@ -61,19 +61,19 @@ The Trump Administration's Medicare GLP-1 deal establishes $245/month pricing (8
 
 
 ### Additional Evidence (challenge)
-*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16*
+*Source: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk | Added: 2026-03-16*
 
 The sarcopenic obesity mechanism creates a pathway where GLP-1s may INCREASE healthcare costs in elderly populations: muscle loss during treatment + high discontinuation (64.8% at 1 year) + preferential fat regain = sarcopenic obesity → increased fall risk, fractures, disability, and long-term care needs. This directly challenges the Medicare cost-savings thesis by creating NEW healthcare costs (disability, falls, fractures) that may offset cardiovascular and metabolic savings.
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16*
+*Source: 2025-12-01-who-glp1-global-guidelines-obesity | Added: 2026-03-16*
 
 WHO issued conditional recommendations (not full endorsements) for GLP-1s in obesity treatment, explicitly acknowledging 'limited long-term evidence.' The conditional framing signals institutional uncertainty about durability of outcomes and cost-effectiveness at population scale. WHO requires countries to 'consider local cost-effectiveness, budget impact, and ethical implications' before adoption, suggesting the chronic use economics remain unproven for resource-constrained health systems.
 
 
 ### Additional Evidence (challenge)
-*Source: [[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]] | Added: 2026-03-16*
+*Source: 2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes | Added: 2026-03-16*
 
 Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF the typical semaglutide dose when paired with digital behavioral support, matching clinical trial results at 50% drug cost. If this half-dose protocol proves generalizable, it could fundamentally alter the inflationary cost trajectory by reducing per-patient drug spending while maintaining efficacy.
 
diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md
index 861a1c801..02d161e5c 100644
--- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md
+++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md
@@ -55,13 +55,13 @@ The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16*
+*Source: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk | Added: 2026-03-16*
 
 The discontinuation problem is worse than just lost metabolic benefits - it creates a body composition trap. Patients who discontinue lose 15-40% of weight as lean mass during treatment, then regain weight preferentially as fat without muscle recovery. This means the most common outcome (discontinuation) leaves patients with WORSE body composition than baseline: same or higher fat, less muscle, higher disability risk. Weight cycling on GLP-1s is not neutral - it's actively harmful.
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]] | Added: 2026-03-16*
+*Source: 2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes | Added: 2026-03-16*
 
 Digital behavioral support may partially solve the persistence problem: UK study showed 11.53% weight loss with engagement vs 8% without at 5 months, suggesting the adherence paradox has a behavioral solution component. However, high withdrawal rates in non-engaged groups suggest this requires active participation, not passive app access.